Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84


Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ.

Sameni M, Cavallo-Medved D, Franco OE, Chalasani A, Ji K, Aggarwal N, Anbalagan A, Chen X, Mattingly RR, Hayward SW, Sloane BF.

Breast Cancer Res. 2017 May 15;19(1):56. doi: 10.1186/s13058-017-0847-0.


Cancer stem cells and early stage basal-like breast cancer.

Lo PK, Wolfson B, Zhou Q.

World J Obstet Gynecol. 2016 May 10;5(2):150-161. doi: 10.5317/WJOG.v5.i2.150.


Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.

Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x.


Force-dependent breaching of the basement membrane.

Chang TT, Thakar D, Weaver VM.

Matrix Biol. 2017 Jan;57-58:178-189. doi: 10.1016/j.matbio.2016.12.005. Epub 2016 Dec 23. Review.


The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer.

Krstic M, Macmillan CD, Leong HS, Clifford AG, Souter LH, Dales DW, Postenka CO, Chambers AF, Tuck AB.

BMC Cancer. 2016 Aug 23;16(1):671. doi: 10.1186/s12885-016-2697-z.


Derepression of hTERT gene expression promotes escape from oncogene-induced cellular senescence.

Patel PL, Suram A, Mirani N, Bischof O, Herbig U.

Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):E5024-33. doi: 10.1073/pnas.1602379113. Epub 2016 Aug 8.


Expression pattern and methylation of estrogen receptor α in breast intraductal proliferative lesions.

Mao X, Qiao Z, Fan C, Guo A, Yu X, Jin F.

Oncol Rep. 2016 Oct;36(4):1868-74. doi: 10.3892/or.2016.4988. Epub 2016 Aug 1.


Impact of Histopathological Factors, Patient History and Therapeutic Variables on Recurrence-free Survival after Ductal Carcinoma in Situ: 8-Year Follow-up and Questionnaire Survey.

van Mackelenbergh MT, Lindner CM, Heilmann T, Alkatout I, Elessawy M, Mundhenke C, Maass N, Schem C.

Geburtshilfe Frauenheilkd. 2016 Jan;76(1):46-52.


AMOTL1 Promotes Breast Cancer Progression and Is Antagonized by Merlin.

Couderc C, Boin A, Fuhrmann L, Vincent-Salomon A, Mandati V, Kieffer Y, Mechta-Grigoriou F, Del Maestro L, Chavrier P, Vallerand D, Brito I, Dubois T, De Koning L, Bouvard D, Louvard D, Gautreau A, Lallemand D.

Neoplasia. 2016 Jan;18(1):10-24. doi: 10.1016/j.neo.2015.11.010.


Breast cancer risk factor associations differ for pure versus invasive carcinoma with an in situ component in case-control and case-case analyses.

Ruszczyk M, Zirpoli G, Kumar S, Bandera EV, Bovbjerg DH, Jandorf L, Khoury T, Hwang H, Ciupak G, Pawlish K, Schedin P, Masso-Welch P, Ambrosone CB, Hong CC.

Cancer Causes Control. 2016 Feb;27(2):183-98. doi: 10.1007/s10552-015-0696-z. Epub 2015 Nov 30.


Expression of CD151/Tspan24 and integrin alpha 3 complex in aid of prognostication of HER2-negative high-grade ductal carcinoma in situ.

Romanska HM, Potemski P, Kusinska R, Kopczynski J, Sadej R, Kordek R.

Int J Clin Exp Pathol. 2015 Aug 1;8(8):9471-8. eCollection 2015.


A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone.

Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL, Saskin R, Butler SM, Tuck A, Sengupta S, Elavathil L, Jani PA, Bonin M, Chang MC, Robertson SJ, Slodkowska E, Fong C, Anderson JM, Jamshidian F, Miller DP, Cherbavaz DB, Shak S, Paszat L.

Breast Cancer Res Treat. 2015 Jul;152(2):389-98. doi: 10.1007/s10549-015-3464-6. Epub 2015 Jun 29.


Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast.

Pang JM, Gorringe KL, Wong SQ, Dobrovic A, Campbell IG, Fox SB.

Breast Cancer Res. 2015 Jun 16;17:80. doi: 10.1186/s13058-015-0586-z. Review.


Emerging understanding of multiscale tumor heterogeneity.

Gerdes MJ, Sood A, Sevinsky C, Pris AD, Zavodszky MI, Ginty F.

Front Oncol. 2014 Dec 18;4:366. doi: 10.3389/fonc.2014.00366. eCollection 2014. Review.


Longitudinal noninvasive imaging of progesterone receptor as a predictive biomarker of tumor responsiveness to estrogen deprivation therapy.

Chan SR, Fowler AM, Allen JA, Zhou D, Dence CS, Sharp TL, Fettig NM, Dehdashti F, Katzenellenbogen JA.

Clin Cancer Res. 2015 Mar 1;21(5):1063-70. doi: 10.1158/1078-0432.CCR-14-1715. Epub 2014 Dec 17.


Molecular Markers as Prognostic Factors in DCIS and Small Invasive Breast Cancers.

Sänger N, Engels K, Graf A, Ruckhäberle E, Effenberger KE, Fehm T, Holtrich U, Becker S, Karn T.

Geburtshilfe Frauenheilkd. 2014 Nov;74(11):1016-1022.


Stage of breast cancer progression influences cellular response to activation of the WNT/planar cell polarity pathway.

MacMillan CD, Leong HS, Dales DW, Robertson AE, Lewis JD, Chambers AF, Tuck AB.

Sci Rep. 2014 Sep 10;4:6315. doi: 10.1038/srep06315. Erratum in: Sci Rep. 2015;5:7942. Dosage error in article text..


miR-320a is an independent prognostic biomarker for invasive breast cancer.

Yang H, Yu J, Wang L, Ding D, Zhang L, Chu C, Chen Q, Xu Z, Zou Q, Liu X.

Oncol Lett. 2014 Sep;8(3):1043-1050. Epub 2014 Jun 30.


Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.

Pape-Zambito D, Jiang Z, Wu H, Devarajan K, Slater CM, Cai KQ, Patchefsky A, Daly MB, Chen X.

PLoS One. 2014 Jun 30;9(6):e100488. doi: 10.1371/journal.pone.0100488. eCollection 2014.


Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer.

Park SY, Seo AN, Jung HY, Gwak JM, Jung N, Cho NY, Kang GH.

PLoS One. 2014 Jun 27;9(6):e100429. doi: 10.1371/journal.pone.0100429. eCollection 2014.

Supplemental Content

Support Center